Rice Hall James & Associates LLC Acquires 408,422 Shares of scPharmaceuticals, Inc. (NASDAQ:SCPH)

Rice Hall James & Associates LLC increased its holdings in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 41.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,398,057 shares of the company's stock after purchasing an additional 408,422 shares during the period. Rice Hall James & Associates LLC owned approximately 2.78% of scPharmaceuticals worth $3,677,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in SCPH. Assenagon Asset Management S.A. acquired a new position in shares of scPharmaceuticals during the 1st quarter worth about $33,000. ProShare Advisors LLC acquired a new position in shares of scPharmaceuticals during the 4th quarter worth about $48,000. Price T Rowe Associates Inc. MD acquired a new position in shares of scPharmaceuticals during the 4th quarter worth about $54,000. Wells Fargo & Company MN lifted its position in shares of scPharmaceuticals by 110.5% during the 4th quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock worth $65,000 after purchasing an additional 9,663 shares during the last quarter. Finally, Corebridge Financial Inc. raised its holdings in scPharmaceuticals by 29.0% in the 4th quarter. Corebridge Financial Inc. now owns 19,586 shares of the company's stock valued at $69,000 after acquiring an additional 4,406 shares in the last quarter. Institutional investors and hedge funds own 89.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SCPH. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, March 20th. Maxim Group cut their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 20th.

scPharmaceuticals Stock Performance

scPharmaceuticals stock traded up $0.33 during trading hours on Thursday, hitting $4.86. The stock had a trading volume of 476,278 shares, compared to its average volume of 378,114. The company has a 50-day moving average of $3.77 and a two-hundred day moving average of $3.27. The company has a quick ratio of 4.61, a current ratio of 5.48 and a debt-to-equity ratio of 3.86. The company has a market cap of $256.56 million, a PE ratio of -2.54 and a beta of 0.38. scPharmaceuticals, Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative net margin of 216.24% and a negative return on equity of 594.07%. The company had revenue of $11.75 million during the quarter, compared to the consensus estimate of $11.63 million. On average, equities research analysts anticipate that scPharmaceuticals, Inc. will post -1.53 EPS for the current fiscal year.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.